{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:06:14Z","timestamp":1775513174459,"version":"3.50.1"},"reference-count":58,"publisher":"Wiley","issue":"S81","license":[{"start":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T00:00:00Z","timestamp":1450310400000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Andy Lockley of Bioscript Medical Ltd (Macclesfield, UK)"},{"name":"Novo Nordisk Health Care AG (Zurich, Switzerland)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Women and girls may experience increased bleeding symptoms as carriers of haemophilia. They can also be affected by other hereditary bleeding diatheses such as von Willebrand disease, platelet dysfunction defects or deficiencies of coagulation factors (F) such as FI, FII, FV, FVII, FX, FXI and FXIII. In addition to general bleeding symptoms, such disorders pose unique problems for women due to their impact on reproductive health. Women and adolescent girls with undiagnosed bleeding disorders frequently experience heavy menstrual bleeding (HMB; menorrhagia), leading to impairment of daily activities. Other gynaecological and obstetric manifestations, for example miscarriage, bleeding during pregnancy and postpartum haemorrhage (PPH), can occur. Treatment for HMB should consider patient wishes relating to preservation of fertility, and management options include hormonal measures, desmopressin, antifibrinolytics, platelet concentrate transfusions and clotting factor therapy. During pregnancy, monitoring clotting factor levels informs the need for prophylactic therapy; subsequent haemostatic cover can minimise PPH. Under\u2010recognition of bleeding disorders in females may lead to inappropriate, or lack of, treatment. This may be avoided by increased disease awareness, prompt and accurate diagnosis, and a multidisciplinary approach to patient care. This review considers the range of hereditary bleeding disorders that may affect women and adolescent girls, and their evaluation and management.<\/jats:p>","DOI":"10.1111\/ejh.12580","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T16:17:00Z","timestamp":1450369020000},"page":"2-10","source":"Crossref","is-referenced-by-count":44,"title":["Improving care and treatment options for women and girls with bleeding disorders"],"prefix":"10.1111","volume":"95","author":[{"given":"Roshni","family":"Kulkarni","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Human Development Center for Bleeding and Clotting Disorders Michigan State University East Lansing MI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,12,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02558.x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04372.x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2007.CDC11"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02563.x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2014.07.040"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3329\/jhpn.v30i2.11294"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60704-0"},{"key":"e_1_2_10_9_1","unstructured":"On Demand Video: Women's Lives Matter: The Impact of Maternal Death on Families & Communities 2014. Available at:http:\/\/fxb.harvard.edu\/womens-lives-matter\/(accessed 15\u00a0January 2015)."},{"key":"e_1_2_10_10_1","unstructured":"Centers for Disease Control and Prevention.Blood Disorders in Women. Available at:http:\/\/www.cdc.gov\/ncbddd\/blooddisorders\/women\/research.html(accessed 15 August 2014)."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2012.07.010"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/152460902753473444"},{"key":"e_1_2_10_13_1","unstructured":"HealthyPeople.gov. Available at:http:\/\/healthypeople.gov\/2020(accessed 15 August 2014)."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1225757"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1349221"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0595"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01314.x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.268"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12368"},{"key":"e_1_2_10_20_1","unstructured":"Mauser\u2010BunschotenEP.Symptomatic Carriers of Hemophilia. World Federation of Hemophilia. Treatment of Hemophilia Series No. 46 2008. Available at:http:\/\/www1.wfh.org\/publications\/files\/pdf-1202.pdf(accessed 16\u00a0September 2014)."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000083"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04653.x"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01792.x"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02426.x"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3879"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1647493"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12364"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogc.2008.12.002"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-200611000-00059"},{"key":"e_1_2_10_30_1","first-page":"16","article-title":"Menorrhagia","volume":"80","author":"Smith H","year":"2013","journal-title":"S Afr Pharm J"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.474"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02315.x"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01108.x"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12259"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e3283566af9"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68397-9"},{"key":"e_1_2_10_37_1","volume-title":"State of the World Population 2013. Motherhood in Childhood: Facing the Challenge of Adolescent Pregnancy","author":"United Nations Population Fund (UNFPA)","year":"2013"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02557.x"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1701-2163(16)30551-5"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03182.x"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01663.x"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01847.x"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03499.x"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation.V2012.1.152.3798226"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-574160"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1990.tb16249.x"},{"key":"e_1_2_10_47_1","unstructured":"KadirRA JamesAH.Reproductive Health in Women with Bleeding Disorders. World Federation of Hemophilia. Treatment of Hemophilia Series No. 48 2009. Available at:http:\/\/www1.wfh.org\/publication\/files\/pdf-1206.pdf(accessed 15\u00a0August 2014)."},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07610.x"},{"key":"e_1_2_10_49_1","unstructured":"Novo Nordisk.NovoSeven\u00aeSummary of Product Characteristics 2014. Available at:http:\/\/www.medicines.org.uk\/EMC\/medicine\/21171\/SPC\/NovoSeven+1+mg+(50KIU)+.+NovoSeven+2+mg+(100+KIU)+.+NovoSeven+5+mg+(250+KIU)+.+NovoSeven+8+mg+(400+KIU)+powder+and+solvent+for+solution+for+injection\/(accessed 15 August 2014)."},{"key":"e_1_2_10_50_1","unstructured":"Novo Nordisk Press Release 2014. Available at:http:\/\/press.novonordisk-us.com\/2014-07-07-FDA-Approves-NovoSeven-RT-for-the-Treatment-of-Glanzmanns-Thrombasthenia-GT-With-Refractoriness(accessed 15 January 2015). [Reference was added subsequent to the symposium whilst drafting the manuscript]."},{"key":"e_1_2_10_51_1","unstructured":"Novo Nordisk.NovoThirteen\u00aeSummary of Product Characteristics 2014. Available at:http:\/\/ec.europa.eu\/health\/documents\/community-register\/2012\/20120903123586\/anx_123586_en.pdf(accessed 15 August 2014)."},{"key":"e_1_2_10_52_1","unstructured":"Novo Nordisk.NovoEight\u00aeSummary of Product Characteristics 2014. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002719\/WC500157553.pdf(accessed 15 August 2014)."},{"key":"e_1_2_10_53_1","unstructured":"European Medicines Agency.Guideline on Core SmPC for Human Plasma Derived and Recombinant Coagulant Factor IX Products. 24 May 2012. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500128994.pdf(accessed 15 August 2014)."},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182839e0e"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2011.04.025"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02573.x"},{"key":"e_1_2_10_57_1","unstructured":"Bolton\u2010MaggsPHB.The Rare Coagulation Disorders. World Federation of Hemophilia. Treatment of Hemophilia Series No. 36 2006. Available at:http:\/\/www1.wfh.org\/publication\/files\/pdf-1188.pdf(accessed 15 August 2014)."},{"key":"e_1_2_10_58_1","unstructured":"US Department of Health and Human Services. National Institutes of Health. National Heart Lung and Blood Institute.The Diagnosis Evaluation and Management of von Willebrand Disease. NIH Publication No. 08\u20105832 December 2007. Available at:http:\/\/www.nhlbi.nih.gov\/files\/docs\/guidelines\/vwd.pdf(accessed 15 August 2014)."},{"key":"e_1_2_10_59_1","unstructured":"Centers for Disease Control and Prevention Screening Tool for Identifying Women with Menorrhagia for Testing and Evaluation for Underlying Bleeding Disorders. Available at:http:\/\/www.cdc.gov\/ncbddd\/blooddisorders\/women\/documents\/menorrhagiafortesting.pdf(accessed 15 January 2015)."}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12580","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:52:56Z","timestamp":1694479976000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":58,"journal-issue":{"issue":"S81","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1111\/ejh.12580"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12580","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}